CanARY Study : The effect of Cannabidiol on positive psychotic symptoms in At Risk for psychosis Youth

This dataset captures data from a randomized controlled trial evaluating the feasibility of cannabidiol (CBD) as a treatment for young people aged 12-25 at Ultra-High Risk (UHR) of psychosis. It includes information on participants' adherence to the intervention, which involved daily doses of 600mg or 1000mg of CBD or a placebo over 12 weeks. The dataset records clinical assessments, adverse events, medication adherence, and biomarker data (e.g., blood, urine, hair samples) collected at multiple time points, including baseline, weeks 4, 8, 12, and follow-up visits up to 104 weeks. The primary outcome focuses on the effectiveness of CBD in reducing subthreshold psychotic symptoms.